Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
Rhea-AI Summary
Artelo Biosciences (Nasdaq: ARTL) reported that the Japanese Patent Office issued a notification of allowance with a Decision to Grant for patent claims covering the intended commercial formulation of ART27.13, a peripherally selective dual cannabinoid agonist dispersed in polyethylene glycol.
The allowed claims align with those in the United States and Europe, with all three jurisdictions expected to provide protection through 2041, strengthening ART27.13’s global intellectual property position. ART27.13 is in two Phase 2 trials: CAReS in cancer-related anorexia, which has shown early weight-stabilizing signals, and DREAM in glaucoma or ocular hypertension, with initial results anticipated in the fourth quarter.
Positive
- Japanese patent allowance for ART27.13 formulation with expected protection through 2041
- ART27.13 IP now at issued or allowance status in United States, Europe, and Japan
- Prior Phase 1 study in Japan reported no major safety or tolerability concerns
- CAReS Phase 1 showed ART27.13 was well tolerated with early weight-loss stabilization in 60%+ of participants
- CAReS Phase 2 interim: highest 1300 µg dose reversed anorexia while placebo group continued losing weight
- DREAM Phase 2 glaucoma study externally funded with initial results expected in Q4
Negative
- None.
News Explained
The Japanese allowance applies to ART27.13, which Artelo says was fully licensed to it in 2019; the disclosure adds patent status to an existing license relationship, rather than announcing a new transaction involving the company’s common ownership.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 17 | U.S. patent allowance | Positive | -8.8% | U.S. patent allowance for ART27.13 commercial formulation preceded a negative 24-hour reaction. |
| Aug 13 | Quarterly earnings report | Neutral | +3.5% | Quarterly results and pipeline update accompanied an $11.0 million financing. |
| Aug 10 | Phase 2 trial launch | Positive | -2.2% | First patient was dosed in the DREAM Phase 2 glaucoma study. |
| Jul 22 | CBD efficacy analysis | Negative | -4.5% | Review of over 50 studies found low-dose CBD generally lacked therapeutic evidence. |
| Jul 16 | Nonclinical pain study | Positive | -0.9% | Nonclinical ART26.12 study reported pain reduction and reduced stomach tissue damage. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
ARTL's recent news reactions were mixed, including negative responses to several positive or potentially positive development updates.
Key Terms
notice of allowance regulatory
decision to grant regulatory
polyethylene glycol technical
intraocular pressure medical
peripherally selective dual cannabinoid agonist medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company’s patent application covering the intended commercial formulation of ART27.13, Artelo’s peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials.
The allowed claims in Japan protect compositions of ART27.13 dispersed in polyethylene glycol. These claims are consistent with those previously allowed in the United States and Europe, and all jurisdictions are expected to provide patent protection through 2041. This brings Artelo’s intellectual property estate for ART27.13 to issued or allowance status in three major pharmaceutical markets, the United States, Japan, and Europe, and further strengthens the program’s global IP position while supporting its long-term commercial potential.
“Receiving this allowance decision in Japan represents another important advancement in our global intellectual property and clinical development strategy for ART27.13,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “The innovator of our investigational drug, AstraZeneca, previously conducted a Phase 1 safety study with ART27.13 in Japan, with no major safety or tolerability concerns, and had concluded the plasma exposure and adverse event profiles were comparable between Japanese and Caucasian participants.” ART27.13 was fully licensed to Artelo in 2019.
Currently being evaluated in the Phase 2 portion of CAReS targeting cancer-related anorexia, ART27.13 was well-tolerated in the Phase 1 stage and showed early signs of stabilizing or reversing weight loss in more than
ART27.13 is also being evaluated in the DREAM study, a pilot Phase 2 in people with glaucoma or ocular hypertension. Funded by Glaucoma UK and the HSC R&D Division in the UK, the investigator-led study is evaluating ART27.13's potential at a 600 µg orally administered daily dose to reduce intraocular pressure, alongside additional assessments of visual acuity, body weight, mood, safety and tolerability. Initial results are anticipated in the fourth quarter of this year.
“With allowances now secured in the United States, Europe and Japan for claims covering our intended commercial formulation, we believe we have established a strong foundation for ART27.13 across three of the world’s major pharmaceutical markets. This growing patent estate further enhances the strategic and commercial value of the program as ART27.13 advances in multiple potential indications,” concluded Mr. Gorgas.
About ART27.13
ART27.13 is a dual cannabinoid agonist and novel benzimidazole derivative. Initially developed by AstraZeneca plc, ART27.13 has been in over seven clinical studies with nearly 300 participants. It is primarily being developed as a once-daily, orally administered agent selectively targeting peripheral CB1 and CB2 receptors, with the potential to reduce muscle degeneration while improving body weight, appetite, and quality of life in cancer patients. Importantly, the drug enables systemic metabolic effects while minimizing central nervous system-mediated toxicity. Artelo is conducting a Phase 2 named the Cancer Appetite Recovery Study (CAReS) evaluating ART27.13 as a supportive care therapy for cancer patients suffering from anorexia and weight loss. Interim Phase 2 data revealed patients who had lost at least
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial expertise to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
